Enoblituzumab (MGA271) is a humanized IgG1κ mAb with enhanced ADCC. Its target is the B7-H3 (CD276) member of the B7 family of immune regulators [2
]. It has been engineered to enhance effector-mediated antitumor function via
increased affinity for the activating receptor CD16A (FcγRIII) and decreased binding to the inhibitory receptor CD32B (FcγRIIB).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
BLAST sequence analysis identifies exact matches with antibody peptides claimed in patent US8802091, and specifically with a construct designated as hBRCA84D-2 [1